Ipsen Q3 Sales Rise 28%, Company Upgrades FY26 Outlook
Ipsen said third-quarter total sales rose 28%, helped by its rare disease division, and upgraded its annual outlook.
PARIS (dpa-AFX) - Ipsen S.A. (IPSEF.PK, IPSEY, IPN.PA, I7G.F), a biopharmaceutical company, said Thursday that its third-quarter total sales rose 28.3 percent, helped by strong performance in its rare disease division. The company also upgraded its annual outlook.The company reported third quarter…